蔡林

北京大学人民医院皮肤科主任医师，副教授，硕士生导师。 1991年毕业于北京医科大学医疗系，毕业后一直在北京大学人民医院皮肤科工作，从事皮肤病的临床、教学和研究30余年，临床经验丰富。主要社会兼职有：中国康复医学会皮肤病康复专委会常委及银屑病组副组长；中华医学会皮肤性病委员会美容学组委员；海峡两岸医药卫生交流协会风湿免疫病学专业委员会银屑病关节炎学组副组长；中国食品药品监督管理局评审专家；卫生部医疗事故技术鉴定专家库成员；北京市劳动能力鉴定委员会医疗卫生专家。先后在日本富山医科药科大学和悉尼大学作高级访问学者。曾获得国家自然科学基金、中华医学会基金及北京大学985科研基金等基金资助。在国内外核心期刊发表论文百余篇（其中SCI论文30余篇），参与著书7部。近20年来一直主持皮肤科药物临床试验工作，参加国际、国内多中心临床试验几十项，主要参与各种生物制剂（阿达木单抗、司库奇尤单抗、乌司奴单抗、度普利尤单抗等）及小分子药（苯维莫得软膏、托法替布、TYK2等）治疗银屑病及银屑病关节炎和特应性皮炎的药物临床研究工作，在临床诊疗与药物临床研究上有着丰富的经验。 代表性文章： 1.Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017 Jan 31（1）. 89-95. 2.Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis。Chinese Medical Journal 2020;133(22)：2665-73. 3.Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J 2020; 133(24)：2905-2909. 4.Cai L, Zhang JZ, Zheng M, Zhang SF, Patekar M. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.. Chin Med J 2021; 134(21)：2629-2631. 5.Cai L. Li LF. Cheng H. Ding YF. Biao ZS. Zhang SF. Geng SM. Liu QZ. Fang H. Song ZQ. Lu Y. Li SS. Guo Q. Tao J. He L. Gu J. Yang QP. Han XP. Gao XH. Deng DQ. Li SQ. Wang QY. Zhu J. Zhang JZ. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther; 2022 Jan.39（1）：583-597.

海峡两岸医药卫生交流协会风湿免疫病学专业委员会银屑病关节炎学组副组长 中华医学会皮肤性病委员会治疗学组、美容学组委员 中国康复医学会皮肤病康复专委会常委，银屑病组副组长 中华医学会北京分会皮肤科委员会委员 中国食品药品监督管理局评审专家 卫生部医疗事故技术鉴定专家库成员 北京市劳动能力鉴定委员会医疗卫生专家

代表性文章： 1.Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017 Jan 31（1）. 89-95. 2.Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis。Chinese Medical Journal 2020;133(22)：2665-73. 3.Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J 2020; 133(24)：2905-2909. 4.Cai L, Zhang JZ, Zheng M, Zhang SF, Patekar M. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.. Chin Med J 2021; 134(21)：2629-2631. 5.Cai L. Li LF. Cheng H. Ding YF. Biao ZS. Zhang SF. Geng SM. Liu QZ. Fang H. Song ZQ. Lu Y. Li SS. Guo Q. Tao J. He L. Gu J. Yang QP. Han XP. Gao XH. Deng DQ. Li SQ. Wang QY. Zhu J. Zhang JZ. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther; 2022 Jan.39（1）：583-597.

临床医师奖、优秀教师奖及人民医院优秀员工